These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1220 related articles for article (PubMed ID: 29895964)

  • 21. Progress in the development of new drugs in Alzheimer's disease.
    Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
    J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease: Recent treatment strategies.
    Vaz M; Silvestre S
    Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
    Ceyzériat K; Zilli T; Millet P; Frisoni GB; Garibotto V; Tournier BB
    Curr Alzheimer Res; 2020; 17(2):112-125. PubMed ID: 32129164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau immunotherapies for Alzheimer's disease.
    Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
    Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
    Bakota L; Brandt R
    Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.
    Takahashi RH; Capetillo-Zarate E; Lin MT; Milner TA; Gouras GK
    Neurobiol Aging; 2010 Jul; 31(7):1145-52. PubMed ID: 18771816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.
    Iqbal K; Liu F; Gong CX
    Biochem Pharmacol; 2014 Apr; 88(4):631-9. PubMed ID: 24418409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spreading of Pathology in Alzheimer's Disease.
    Lv ZY; Tan CC; Yu JT; Tan L
    Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics.
    Pritchard SM; Dolan PJ; Vitkus A; Johnson GV
    J Cell Mol Med; 2011 Aug; 15(8):1621-35. PubMed ID: 21348938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
    Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
    PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease.
    Huang HC; Jiang ZF
    J Alzheimers Dis; 2009; 16(1):15-27. PubMed ID: 19158417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
    Zhang H; Wei W; Zhao M; Ma L; Jiang X; Pei H; Cao Y; Li H
    Int J Biol Sci; 2021; 17(9):2181-2192. PubMed ID: 34239348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS; Rauw G; Baker GB; Kar S
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.
    Attems J; Jellinger KA
    Clin Neuropathol; 2006; 25(6):265-71. PubMed ID: 17140156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities.
    Tran HT; LaFerla FM; Holtzman DM; Brody DL
    J Neurosci; 2011 Jun; 31(26):9513-25. PubMed ID: 21715616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.